Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil

N/ANo Longer AvailableNCT00866983

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Overview

The purpose of this study is to provide sildenafil therapy to patients who completed the A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio™ is not supplied by Health Secretary, and are judged by the Investigator to derive clinical benefit from continued treatment with Sildenafil. It will be supplied until patient gets access to Sildenafil through Brazilian State Health Secretary from where patient resides.

Study Type

EXPANDED_ACCESS

Conditions

Pulmonary Arterial Hypertension

Interventions

sildenafil (Revatio) 20 mg TIDDRUG

To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject who completed the A1481244 study and are judged by the Investigator to derive clinical benefit from continuous treatment with Sildenafil 20 mg therapy. * Subject who resides in a Brazilian State where Sildenafil is not supplied by State Health Secretary. Exclusion Criteria: * Pregnant or lactating women. * Current participation in other studies and during study participation.

Locations (2)

Pfizer Investigational Site

Porto Alegre, Rio Grande do Sul, Brazil

Pfizer Investigational Site

São Paulo, São Paulo, Brazil

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.